“…It is well-known that IL-27 possesses antitumor activities against a variety of tumor types (Nagai et al, 2010;Di Carlo et al, 2014;Yoshida and Hunter, 2015;Yoshimoto et al, 2015). IL-27 is a polymorphic gene and several studies examined the association between IL-27 gene polymorphisms and risk of various cancers including, non-small-cell lung cancer (NSCLC) (Ge and Xiao, 2016), acute lymphoblastic leukemia (ALL) (Ghavami et al, 2018), nasopharyngeal carcinoma (NPC) (Wei et al, 2009;Pan et al, 2012), colorectal cancer (CRC) (Guo et al, 2012;Huang et al, 2012;Lyu et al, 2015), prostate cancer (PCa) (Munretnam et al, 2014), papillary thyroid carcinoma (PTC) (Zhang et al, 2015;Nie et al, 2017), hepatocellular carcinoma (HCC) (Peng et al, 2013), renal cell carcinoma (RCC) (Pu et al, 2015), osteosarcoma (Tang et al, 2014), esophageal cancer (Tao et al, 2012), cervical cancer (Wang et al, 2016), endometrial cancer (Yu et al, 2016), ovarian cancer (Zhang et al, 2014b), breast cancer (Zhang et al, 2014a), glioma (Zhao et al, 2009), and bladder cancer (Zhou et al, 2015). However, the findings of these studies have been controversial.…”